154 related articles for article (PubMed ID: 18318994)
1. Establishment and characterization of a cell based artificial antigen-presenting cell for expansion and activation of CD8+ T cells ex vivo.
Gong W; Ji M; Cao Z; Wang L; Qian Y; Hu M; Qian L; Pan X
Cell Mol Immunol; 2008 Feb; 5(1):47-53. PubMed ID: 18318994
[TBL] [Abstract][Full Text] [Related]
2. 4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy.
Zhang H; Snyder KM; Suhoski MM; Maus MV; Kapoor V; June CH; Mackall CL
J Immunol; 2007 Oct; 179(7):4910-8. PubMed ID: 17878391
[TBL] [Abstract][Full Text] [Related]
3. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
4. 4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes.
Sluijter BJ; van den Hout MF; Stam AG; Lougheed SM; Suhoski MM; van den Eertwegh AJ; van den Tol MP; van Leeuwen PA; Meijer S; Scheper RJ; June CH; de Gruijl TD; Santegoets SJ
Clin Immunol; 2010 Nov; 137(2):221-33. PubMed ID: 20708974
[TBL] [Abstract][Full Text] [Related]
5. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.
Suhoski MM; Golovina TN; Aqui NA; Tai VC; Varela-Rohena A; Milone MC; Carroll RG; Riley JL; June CH
Mol Ther; 2007 May; 15(5):981-8. PubMed ID: 17375070
[TBL] [Abstract][Full Text] [Related]
6. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo.
Yan X; Johnson BD; Orentas RJ
Immunology; 2004 May; 112(1):105-16. PubMed ID: 15096190
[TBL] [Abstract][Full Text] [Related]
7. Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells.
Zhao Y; Croft M
Immunol Lett; 2012 Jan; 141(2):220-6. PubMed ID: 22037570
[TBL] [Abstract][Full Text] [Related]
8. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
9. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes.
Thomas AK; Maus MV; Shalaby WS; June CH; Riley JL
Clin Immunol; 2002 Dec; 105(3):259-72. PubMed ID: 12498807
[TBL] [Abstract][Full Text] [Related]
10. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function.
Wen T; Bukczynski J; Watts TH
J Immunol; 2002 May; 168(10):4897-906. PubMed ID: 11994439
[TBL] [Abstract][Full Text] [Related]
11. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
Zeng W; Su M; Anderson KS; Sasada T
Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
[TBL] [Abstract][Full Text] [Related]
12. Co-stimulation with 4-1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells.
Habib-Agahi M; Phan TT; Searle PF
Int Immunol; 2007 Dec; 19(12):1383-94. PubMed ID: 17977894
[TBL] [Abstract][Full Text] [Related]
13. [The role of costimulatory molecule 4-1BB and CD28 in activating of various T cell subsets from human peripheral blood].
Wu JY; Qian F; Lu HZ; Wang W; Li BQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Sep; 20(5):533-6. PubMed ID: 15367340
[TBL] [Abstract][Full Text] [Related]
14. Preferential T cell expansion by artificial antigen presenting cells expressing 4-1BBL alone or in combination with CD80 or CD86.
Habib-Agahi M; Jaberipour M; Phan TT; Searle PF
Iran J Immunol; 2008 Sep; 5(3):136-47. PubMed ID: 18791280
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation.
Davis CC; Marti LC; Sempowski GD; Jeyaraj DA; Szabolcs P
Cancer Res; 2010 Jul; 70(13):5249-58. PubMed ID: 20530666
[TBL] [Abstract][Full Text] [Related]
16. Genetically engineered fixed K562 cells: potent "off-the-shelf" antigen-presenting cells for generating virus-specific T cells.
Tanimoto K; Muranski P; Miner S; Fujiwara H; Kajigaya S; Keyvanfar K; Hensel N; Barrett AJ; Melenhorst JJ
Cytotherapy; 2014 Jan; 16(1):135-46. PubMed ID: 24176543
[TBL] [Abstract][Full Text] [Related]
17. Changes in lymphocytes' telomerase activity by 4-1BB costimulation.
Ahmad HT; Mansooreh J; Fereshteh M; Mojtaba H
J Cancer Res Ther; 2014; 10(4):998-1003. PubMed ID: 25579543
[TBL] [Abstract][Full Text] [Related]
18. Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells.
Rudolf D; Silberzahn T; Walter S; Maurer D; Engelhard J; Wernet D; Bühring HJ; Jung G; Kwon BS; Rammensee HG; Stevanović S
Cancer Immunol Immunother; 2008 Feb; 57(2):175-83. PubMed ID: 17657490
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL.
Serghides L; Bukczynski J; Wen T; Wang C; Routy JP; Boulassel MR; Sekaly RP; Ostrowski M; Bernard NF; Watts TH
J Immunol; 2005 Nov; 175(10):6368-77. PubMed ID: 16272289
[TBL] [Abstract][Full Text] [Related]
20. Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L.
Yan X; Johnson BD; Orentas RJ
J Immunol; 2008 Oct; 181(7):4621-31. PubMed ID: 18802064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
